Background: Combined antiretroviral therapy (cART) has reduced the risk of developing Kaposi Sarcoma (KS), however, the residual burden of disease remains unclear. We analyzed the data of a large prospective European multi-cohort project, the Collaboration of Observational HIV Epidemiological Research Europe (COHERE) to examine risk factors at enrolment and KS incidence over 15 years of cART availability. Methodology: We included HIV-infected patients aged >16 years who enrolled in a COHERE cohort after 1.1.1996. We defined cART as a regimen of at least 3 drugs from at least 2 drug classes. Incidence of KS was estimated for patients on cART and not on cART. We calculated incidence rates and ran Cox regression models adjusted for calendar period, age, exposure group, CD4 cell counts, HIV viral load and CDC stage at enrolment (model 1), and origin (model 2). cART was treated as a time-dependent variable. KS cases diagnosed within 30 days after cART start were classified as not on cART. Results: We included 156,667 patients from 24 cohorts (median age 35 years, 73% male, median CD4 cell count at enrolment 338 cells/μL). 25,564 patients never started any antiretroviral therapy; 23,342 patients started mono- or dual-therapy, which was followed by cART in 17,703 patients; and 107,761 patients started cART being treatment naive. During 877,920 person-years (pys) 2,090 patients developed KS. The incidence was 393/100,000 pys (95% CI 366-421) among patients not receiving cART and 123/100,000 pys (95% CI 115-133) among patients on cART for more than 6 months (HR 0.21, 95% CI 0.18-0.25; model 1). In the first 6 months of cART, the incidence was 976/100,000 pys (95% CI 89-1070). The risk of developing KS was higher among patients aged > 50 years, among men, men who have sex with men, and patients with low CD4 counts and high HIV viral loads at enrolment (Table 1). However, there was no evidence for an effect of CDC stage at enrolment on the risk of developing KS. KS incidence decreased over calendar years. Model 2 confirms these results and indicates a higher risk for patients of African origin. Conclusions: In the era of cART the incidence of KS remains high during the first months on cART, possibly because of IRIS. Male patients, particularly men who have sex with men, patients of African origin or aged above 50 years are important risk groups. Patients enrolling into the cohort with uncontrolled HIV viral replication and advanced immunosuppression are also at increased risk of developing KS.